Diabetes Associated with Single Gene Defects and Chromosomal Abnormalities
Editor(s): Barbetti, F. (Rome)Ghizzoni, L. (Turin)
Guaraldi, F. (Turin)
(DOI:10.1159/000454746)
Diabetes in Myotonic DystrophyDahlqvist J.R. · Vissing J.Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: March 21, 2017
Cover Date: 2017
Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 0
ISBN: 978-3-318-06024-9 (Print)
eISBN: 978-3-318-06025-6 (Online)
Abstract
The myotonic dystrophies are the most common muscular dystrophies worldwide. There are 2 major types of the myotonic dystrophies: type 1 (DM1) and type 2 (DM2). Both DM1 and DM2 are microsatellite expansion disorders in which a sequence of nucleotides expands to a pathogenic range. The transcripts containing repeat expansions interfere with the normal RNA metabolism resulting in disrupted regulation of alternative splicing. DM1 and DM2 are multisystem diseases, affecting skeletal muscle, the heart, the central nervous system, the eyes, and the endocrine system. Individuals with DM1 and DM2 have peripheral insulin resistance and increased proinsulin levels that can lead to glucose intolerance, hyperinsulinemia, and an increased risk of developing type 2 diabetes. In studies on individuals with DM1, impaired glucose tolerance was found in 15% compared to 10% in the background population and diabetes in 6-9 versus 3-4% in the general population.
© 2017 S. Karger AG, Basel
References
-
Lee JE, Cooper TA: Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 2009;37:1281-1286.
-
Ulane CM, Teed S, Sampson J: Recent advances in myotonic dystrophy type 2. Curr Neurol Neurosci Rep 2014;14:429.
-
Turner C, Hilton-Jones D: Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol 2014;27:599-606.
-
Santoro M, Masciullo M, Bonvissuto D, Bianchi ML, Michetti F, Silvestri G: Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2. Mol Cell Biochem 2013;380:259-265.
-
Day JW, Ranum LP: RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord 2005;15:5-16.
-
Lund M, Diaz LJ, Ranthe MF, Petri H, Duno M, Juncker I, Eiberg H, Vissing J, Bundgaard H, Wohlfahrt J, Melbye M: Cardiac involvement in myotonic dystrophy: a nationwide cohort study. Eur Heart J 2014;35:2158-2164.
-
Petri H, Witting N, Ersboll MK, Sajadieh A, Duno M, Helweg-Larsen S, Vissing J, Kober L, Bundgaard H: High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: a cross-sectional study. Int J Cardiol 2014;174:31-36.
-
Orngreen MC, Arlien-Soborg P, Duno M, Hertz JM, Vissing J: Endocrine function in 97 patients with myotonic dystrophy type 1. J Neurol 2012;259:912-920.
-
Matsumura T, Iwahashi H, Funahashi T, Takahashi MP, Saito T, Yasui K, Saito T, Iyama A, Toyooka K, Fujimura H, Shinno S: A cross-sectional study for glucose intolerance of myotonic dystrophy. J Neurol Sci 2009;276:60-65.
-
Dahlqvist JR, Orngreen MC, Witting N, Vissing J: Endocrine function over time in patients with myotonic dystrophy type 1. Eur J Neurol 2015;22:116-122.
-
Moxley RT, Griggs RC, Goldblatt D, VanGelder V, Herr BE, Thiel R: Decreased insulin sensitivity of forearm muscle in myotonic dystrophy. J Clin Invest 1978;62:857-867.
-
Moxley RT, Corbett AJ, Minaker KL, Rowe JW: Whole body insulin resistance in myotonic dystrophy. Ann Neurol 1984;15:157-162.
-
Glumer C, Jorgensen T, Borch-Johnsen K; Inter99 Study: Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 Study. Diabetes Care 2003;26:2335-2340.
-
Savkur RS, Philips AV, Cooper TA: Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001;29:40-47.
-
Perseghin G, Caumo A, Arcelloni C, Benedini S, Lanzi R, Pagliato E, Sereni LP, Testolin G, Battezzati A, Comi G, Comola M, Luzi L: Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy. Diabetes Care 2003;26:2112-2118.
-
Gagnon C, Chouinard MC, Laberge L, Brisson D, Gaudet D, Lavoie M, Leclerc N, Mathieu J: Prevalence of lifestyle risk factors in myotonic dystrophy type 1. Can J Neurol Sci 2013;40:42-47.
-
Tjepkema M: Adult obesity. Health Rep 2006;17:9-25.
-
Kouki T, Takasu N, Nakachi A, Tamanaha T, Komiya I, Tawata M: Low-dose metformin improves hyperglycaemia related to myotonic dystrophy. Diabet Med 2005;22:346-347.
-
Kashiwagi K, Nagafuchi S, Sekiguchi N, Yamagata A, Iwata I, Furuya H, Kato M, Niho Y: Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy. Eur Neurol 1999;41:171-172.
-
Jorgensen ME, Bjerregaard P, Borch-Johnsen K, Witte D: New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab 2010;95:E333-E336.
-
Reyna SM, Tantiwong P, Cersosimo E, Defronzo RA, Sriwijitkamol A, Musi N: Short-term exercise training improves insulin sensitivity but does not inhibit inflammatory pathways in immune cells from insulin-resistant subjects. J Diabetes Res 2013;2013:107805.
-
Orngreen MC, Olsen DB, Vissing J: Aerobic training in patients with myotonic dystrophy type 1. Ann Neurol 2005;57:754-757.
Article / Publication Details
Published online: March 21, 2017
Cover Date: 2017
Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 0
ISBN: 978-3-318-06024-9 (Print)
eISBN: 978-3-318-06025-6 (Online)

Get Permission